AbbVie News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

31.08.22	SkinMedica® Launches Firm & Tone Lotion for Body (PR Newswire)
30.08.22	Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report (PR Newswire)
29.08.22	AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress (PR Newswire)
25.08.22	FDA Oks AbbVie' Imbruvica For Treatment Of Pediatric Patients With Chronic Graft Versus Host Disease (RTTNews)
25.08.22	Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib) (PR Newswire)
17.08.22	Experience the JUVÉDERM® Difference with Allergan Aesthetics (PR Newswire)
03.08.22	Allegan Aesthetics Of AbbVie Gets FDA Approval For Juvederm Volux XC For Jawline Treatment (RTTNews)
03.08.22	FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition (PR Newswire)
31.07.22	Molecular Partners-Aktie: So entstand Molecular Partners aus einer Forschungsgruppe der UZH (finanzen.ch) Krankheiten nicht mit Antikörpern, sondern sogenannten DARPins heilen - das ist der Ansatz von Molecular Partners. Gegründet wurde das Unternehmen 2004 von einer Forschungsgruppe der Universität Zürich.» mehr
29.07.22	AbbVie Confirms FY22 Adj. EPS Outlook - Update (RTTNews)
29.07.22	AbbVie Q2 Profit Increases, beats estimates (RTTNews)
29.07.22	AbbVie Reports Second-Quarter 2022 Financial Results (PR Newswire)
29.07.22	AbbVie: RINVOQ Approved In EU To Treat Adults With Active Non-Radiographic Axial Spondyloarthritis (RTTNews)
29.07.22	RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis (PR Newswire)
28.07.22	Ausblick: AbbVie zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
27.07.22	AbbVie Submits Regulatory Applications To FDA, EMA For Upadacitinib For Crohn's Disease In Adults (RTTNews)
27.07.22	AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's Disease (PR Newswire)
26.07.22	European Commission Approves AbbVie's Rinvoq To Treat Moderate To Severe Ulcerative Colitis (RTTNews)
26.07.22	European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis (PR Newswire)
25.07.22	AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference (PR Newswire)
20.07.22	AbbVie To Collaborate With ISTAR Medical; To Pay $60 Mln To Further Develop MINIject (RTTNews)
20.07.22	AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma (PR Newswire)
18.07.22	AbbVie: EMA's CHMP To Review Marketing Authorization Application For Migraine Drug Atogepant (RTTNews)
18.07.22	AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine (PR Newswire)
14.07.22	Erste Schätzungen: AbbVie stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
08.07.22	AbbVie to Host Second-Quarter 2022 Earnings Conference Call (PR Newswire)
27.06.22	Approximately 15,000 AbbVie Employees to Volunteer Globally to Support Local Communities in Annual Week of Possibilities (PR Newswire)
27.06.22	AbbVie: Europe's CHMP Recommends To Approve Upadacitinib To Treat Active Nr-axSpA Patients (RTTNews)
27.06.22	CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis (PR Newswire)
24.06.22	New Survey Offers Perspective on Mental and Emotional Journey for Patients Diagnosed with Slow-Growing Blood Cancer (PR Newswire)
23.06.22	AbbVie Declares Quarterly Dividend (PR Newswire)
22.06.22	AbbVie: Health Canada Approves Label Extension For MAVIRET To Include Use In Paediatric Patients (RTTNews)
21.06.22	AbbVie Files SNDA For Atogepant For Label Expansion (RTTNews)
21.06.22	AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine (PR Newswire)
17.06.22	Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report providing unrivalled insight into future of industry (PR Newswire)
17.06.22	AbbVie: FDA Approves SKYRIZI In Treatment Of Crohn's Disease (RTTNews)
17.06.22	SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults (PR Newswire)
11.06.22	AbbVie : Phase 2 Trial Of Epcoritamab Shows Clinically Meaningful Efficacy In Large B-cell Lymphoma (RTTNews)
11.06.22	AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hemat... (PR Newswire)
10.06.22	AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients (PR Newswire)
10.06.22	AbbVie : Data Shows Venclyxto/Venclexta Combination Sustained PFS In Chronic Lymphocytic Leukemia (RTTNews)
10.06.22	New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment (PR Newswire)
07.06.22	AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® (AHS) Annual Scientific Meeting (PR Newswire)
02.06.22	ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV (PR Newswire)
02.06.22	AbbVie Presents Positive Results From Phase 3 Trials Of Upadacitinib In Axial Spondyloarthritis (RTTNews)
01.06.22	AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022 (PR Newswire)
27.05.22	The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis (PR Newswire)
27.05.22	The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease (PR Newswire)
24.05.22	ABBV LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV (PR Newswire)
24.05.22	AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester

11.11.24

Börse New York in Grün: S&P 500 zum Handelsende freundlich

11.11.24

Optimismus in New York: S&P 500 am Nachmittag mit Kursplus

11.11.24

NYSE-Handel: S&P 500 mittags freundlich

11.11.24

Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen

02.07.24

Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge

02.07.24

Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten

06.05.24

S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude

26.04.24

Gewinne in New York: S&P 500 am Nachmittag fester

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu AbbVie Inc

Aktien Top/Flop

AbbVie Peer Group Nachrichten

Meistgelesene Nachrichten